[Current Period Performance Forecast](index=1&type=section&id=%E4%B8%80%E3%80%81%E6%9C%AC%E6%9C%9F%E4%B8%9A%E7%BB%A9%E9%A2%84%E8%AE%A1%E6%83%85%E5%86%B5) The company anticipates a significant shift from profit to loss in the first half of 2025, with net profit attributable to shareholders projected to be a substantial loss compared to the prior year's profit Key Financial Performance Indicators | Item | Current Period | Prior Year Period | | :--- | :--- | :--- | | **Net Profit Attributable to Shareholders** | Loss: 28.00 million - 20.00 million yuan | Profit: 0.5535 million yuan | | **Net Profit After Non-Recurring Items** | Loss: 26.00 million - 19.00 million yuan | Profit: 0.1691 million yuan | | **Basic Earnings Per Share** | Loss: 0.0333 - 0.0238 yuan/share | Profit: 0.0007 yuan/share | [Pre-Audit Status of Performance Forecast](index=1&type=section&id=%E4%BA%8C%E3%80%81%E4%B8%9A%E7%BB%A9%E9%A2%84%E5%91%8A%E9%A2%84%E5%AE%A1%E8%AE%A1%E6%83%85%E5%86%B5) The performance forecast data has not been pre-audited by a certified public accountant and represents preliminary estimates by the company's finance department - This performance forecast has not been pre-audited by a certified public accountant[4](index=4&type=chunk) [Explanation of Performance Change](index=1&type=section&id=%E4%B8%89%E3%80%81%E4%B8%9A%E7%BB%A9%E5%8F%98%E5%8A%A8%E5%8E%9F%E5%9B%A0%E8%AF%B4%E6%98%8E) The H1 2025 loss is primarily due to declining profitability in core dental medical services and reduced investment income from the associated company, Fushun Bank - Core business challenges include increased market competition, rising customer acquisition costs, and declining average transaction value in dental medical services, leading to reduced profitability[5](index=5&type=chunk) - Decreased investment income from the associated company, Fushun Bank, due to a decline in the valuation of its financial product investments, is another significant factor contributing to the loss[5](index=5&type=chunk) [Other Relevant Information](index=1&type=section&id=%E5%9B%9B%E3%80%81%E5%85%B6%E4%BB%96%E7%9B%B8%E5%85%B3%E8%AF%B4%E6%98%8E) The company states that the forecast data is preliminary, with final financial figures subject to the official H1 2025 semi-annual report, and advises investors to be aware of investment risks - The forecast data is preliminary, and the definitive financial figures will be based on the company's officially disclosed 2025 semi-annual report[6](index=6&type=chunk) - The company will timely disclose information as required and reminds investors to be mindful of investment risks[7](index=7&type=chunk)

Group 1 - The company held its 24th temporary meeting of the 5th board of directors on July 7, 2025, with all 7 directors present, ensuring compliance with relevant laws and regulations [1] - The board approved a proposal to apply for a loan renewal from Shanxi Bank for an amount not exceeding RMB 113.2 million, aimed at meeting operational liquidity needs [2] - The company's wholly-owned subsidiaries, Jilin Yongda Electric Switch Co., Ltd. and Beijing Rongyu Technology Co., Ltd., will provide collateral for the loan with their property rights, while the company will pledge 20% of its shares in Beijing Wantai Zhonglian Technology Co., Ltd. as additional security [2] Group 2 - The board authorized the chairman or their representative to sign relevant agreements and handle matters related to the loan renewal [2] - The announcement regarding the loan renewal and subsidiary guarantees will be disclosed in designated media outlets [2]

Transaction Overview - The company plans to apply for a one-year loan renewal from Shanxi Bank, with an amount not exceeding RMB 113.2 million to meet operational funding needs [1][3] - The loan will be secured by the company's wholly-owned subsidiaries, Jilin Yongda Electric Switch Co., Ltd. and Beijing Rongyu Technology Co., Ltd., providing mortgage guarantees on their property and land use rights [1][3] - The company will also pledge 20% of its shares in Beijing Wantai Zhonglian Technology Co., Ltd. as collateral for the loan [1][3] Counterparty Information - Shanxi Bank is a non-listed joint-stock company established on April 27, 2021, with a registered capital of approximately RMB 258.94 million [2] Guarantee Agreement Details - The guarantee for the loan includes collateral from the subsidiaries and a pledge of shares, with additional joint liability guarantees from subsidiaries Zhiyu Medical Investment Co., Ltd. and Beijing Lulubai Technology Co., Ltd. [1][2][3] Board of Directors' Opinion - The board supports the loan application as it is essential for the company's operational development and liquidity needs [3] External Guarantee Amount - As of the announcement date, the total external guarantee amount by the company and its subsidiaries is RMB 77.9 million, accounting for 19.57% of the audited net assets for 2024 [3]

关于拟向银行申请续贷并由子公司提供担保的公告 证券代码：002622 证券简称：皓宸医疗 公告编号：2025-016 皓宸医疗科技股份有限公司 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假 记载、误导性陈述或重大遗漏。 一、交易概述 为满足皓宸医疗科技股份有限公司（以下简称"公司"）经营发展需要，补 充公司日常运营所需流动资金，公司拟向山西银行股份有限公司申请期限为一年 的续贷业务，金额不超过人民币 1.132 亿元，由公司全资子公司吉林永大电气开 关有限公司及北京融钰科技有限公司以其合法持有的房屋所有权及土地使用权 提供抵押担保，公司以持有的北京万泰中联科技股份有限公司 20%股权进行质押 为本次续贷业务提供担保，公司全资子公司植钰医疗投资有限公司及北京陆陆捌 科技有限公司为本次续贷业务提供连带责任保证。 公司已于 2025 年 7 月 7 日召开第五届董事会第二十四次临时会议审议通过 上述事项，董事会授权董事长或其授权代表签署相关协议及办理续贷有关事项。 根据相关法律法规及《公司章程》的有关规定，上述事项不属于关联交易，在董 事会审批权限内，无需提交股东大会审议。 二、交易对方基本情 ...

证券代码：002622 证券简称：皓宸医疗 公告编号：2025-015 皓宸医疗科技股份有限公司 第五届董事会第二十四次临时会议决议公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假 记载、误导性陈述或重大遗漏。 皓宸医疗科技股份有限公司（以下简称"公司"）第五届董事会第二十四次 临时会议于 2025 年 7 月 7 日下午 14:30 以现场结合通讯表决的方式召开。本次 会议已于 2025 年 7 月 3 日以电话、电子邮件等方式通知了各位董事。本次会议 由董事长陆璐女士主持，会议应出席董事 7 名，实际出席董事 7 名。此次会议的 召集、召开与表决程序符合《中华人民共和国公司法》和《公司章程》及相关法 律、法规的规定，合法有效。经与会董事认真审议并表决，通过了以下议案： 一、审议通过《关于拟向银行申请续贷并由子公司提供担保的议案》 表决情况：同意 6 票，反对 0 票，弃权 1 票（董事蔡惠燕女士投弃权票，弃 权理由：因所在单位内部决策未形成统一意见，对本次会议议案不参与表决）； 为满足经营发展需要，补充公司日常运营所需流动资金，董事会同意公司向 山西银行股份有限公司申请期限为一年的 ...

Market Overview - The Shanghai Composite Index closed at 3393.26 points, above the six-month moving average, with a change of 0.23% [1] - The total trading volume of A-shares reached 838.618 billion yuan [1] Stocks Breaking Six-Month Moving Average - A total of 184 A-shares have surpassed the six-month moving average today [1] - Notable stocks with significant deviation rates include: - Qitian Technology: 11.69% deviation, closing price 14.38 yuan, with a daily increase of 20.03% and turnover rate of 15.50% [1] - Haochen Medical: 8.62% deviation, closing price 3.12 yuan, with a daily increase of 9.86% and turnover rate of 6.44% [1] - Jinyinhai: 7.58% deviation, closing price 21.00 yuan, with a daily increase of 9.66% and turnover rate of 6.43% [1] Additional Stocks with Deviation Rates - Other stocks with notable performance include: - Guangyun Technology: 7.45% deviation, closing price 14.13 yuan, with a daily increase of 9.20% and turnover rate of 4.78% [1] - Yaowang Technology: 5.93% deviation, closing price 7.12 yuan, with a daily increase of 7.88% and turnover rate of 13.64% [1] - Nuotai Biotech: 5.91% deviation, closing price 55.37 yuan, with a daily increase of 10.36% and turnover rate of 5.58% [1] Summary of Other Stocks - Additional stocks with lower deviation rates that have just crossed the six-month moving average include: - Guangdong Hongtu: just above the six-month line [1] - Xinhe Shares: just above the six-month line [1] - Songjing Shares: just above the six-month line [1]

暗盘资金一眼洞悉庄家意图>> 牙科医疗板块盘初拉升，皓宸医疗（002622）封板涨停，爱迪特（301580）涨超5%，康惠制药 （603139）、悦心健康（002162）、正海生物（300653）、国瓷材料（300285）等均涨超2%。 ...

Core Points - The stock price of Haocen Medical (002622) increased by 1.85% to 2.75 yuan as of May 30, 2025, with a total market capitalization of 2.31 billion yuan [1] - The company plans to enhance the quality management of its dental services and improve its existing medical quality management system [2] - Delun Medical has expanded its outpatient service area by nearly 10,000 square meters and increased the number of dental chairs by over 100 [3] Company Updates - As of December 31, 2024, Haocen Medical had over 1,700 employees [4] - The company will strictly follow accounting standards for impairment provisions in the second quarter [4] - Delun Medical's new outpatient clinic in Zhaoqing opened in May 2025 [4] - There are currently no plans for the company to acquire the remaining shares of Delun Medical [4]

Group 1: Company Overview and Performance - As of December 31, 2024, the company has over 1,700 employees [1] - The company will continue to enhance the quality management of its oral healthcare services and improve its existing medical quality management system [2] Group 2: Business Strategies - In 2025, the company will increase the development of new products and processes in the permanent magnet switch business, optimizing product design to enhance quality and performance [2] - The company aims to expand its market presence by focusing on both regional and industry operations, as well as channel sales [1] Group 3: Financial Management - The company will adhere to accounting standards for impairment provisions, ensuring sustainable development [3] - The company has not yet received the detailed equity change report from the information disclosure obligor [3][4] Group 4: Shareholder Engagement and Future Plans - The company is considering the acquisition of quality assets in the oral healthcare sector and may divest from other businesses to strengthen its core dental services [3] - The company has expanded its dental clinic area by nearly 10,000 square meters and increased the number of dental chairs by over 100 [5]

Group 1 - The core viewpoint of the news is that Haocen Medical has shown a slight increase in stock price and has a market capitalization of 2.318 billion yuan, with a current price-to-book ratio of 6.07 [1] - On May 27, Haocen Medical's main funds saw a net inflow of 86,000 yuan, with a total inflow of 6.7166 million yuan over the past five days [1] - The company specializes in oral medical services and the research, production, and sales of permanent magnet switches and high/low voltage complete equipment [1] Group 2 - In the latest performance report for Q1 2025, Haocen Medical achieved operating revenue of 143 million yuan, a year-on-year decrease of 12.58%, and a net profit of -12,214,580.55 yuan, a year-on-year decrease of 167.13%, with a gross profit margin of 38.50% [1] - The company has recently received several honors, including two new authorized invention patents, three new utility model patents, and various certifications related to energy management and measurement management [1] - The company's PE (TTM) is -51.14, and the industry average PE (TTM) is 38.66, indicating a significant disparity in valuation compared to industry peers [2]